Funding For US FDA Work On Cannabinoids Regulatory Pathway Drives Progress Only So Far

FDA is conducting lab testing on CBD products with funding in its FY2021 appropriations, says senior agency advisor Sharon Mayl. Some work planned work in the area has been delayed by the agency's response to COVID-19.

The US Food and Drug Administration, says senior agency advisor Sharon Mayl, is making use of its fiscal year 2021 appropriation for developing a lawful pathway for using cannabidiol and other cannabinoids in non-drug products but realizes there’s little to show for the work so far.

“We are continuing to evaluate the data that we see on the safety of CBD itself. We’ve also been doing...